Skip to main content
. 2017 Jan 10;37(2):737–746. doi: 10.3892/or.2017.5362

Figure 5.

Figure 5.

Release of both (A) matrix metalloproteinase (MMP)-9 and (B) nuclear factor-κB (NF-κB) p65 activity in melanoma with or without BRAFV600E mutation. *P<0.05 compared to DHMEQ-treated cells; **P<0.05 compared to osteopontin (OPN) + DHMEQ-treated cells. OPN, osteopontin; OD, optical density; PBMCs, peripheral blood mononuclear cells.